Efficacy of Cx601 (Darvadstrocel) for the Treatment of Perianal Fistulizing Crohn's Disease

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

December 1, 2021

Study Completion Date

December 1, 2021

Conditions

Crohn DiseaseFistula Perianal

Interventions

DRUG

Darvadstrocel

Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells around the fistula opening and around the fistula tract

Trial Locations (1)

Medical University of Vienna, Vienna

All Listed Sponsors

lead

Medical University of Vienna

OTHER

NCT05322057 - Efficacy of Cx601 (Darvadstrocel) for the Treatment of Perianal Fistulizing Crohn's Disease | Biotech Hunter | Biotech Hunter